Related Experiment Videos
[Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines]
J J Oosterheert1, M J M Bonten, M M E Schneider
1Universitair Medisch Centrum, afd. Acute Geneeskunde en Infectieziekten, Postbus 85.500, 3508 GA Utrecht.
Abstract:
Community-acquired pneumonia is an important cause of hospital admission and mortality in the adult population. The recommended antibiotic for pneumonia caused by Streptococcus pneumoniae is a beta-lactam antibiotic and, for so-called atypical pathogens, a macrolide. In the US and elsewhere, the current recommendation is to start with a beta-lactam antibiotic and a macrolide or with one of the new quinolones. The available literature consists largely of retrospective studies. Because of possible selection bias in these analyses and inconsistencies in reported outcomes, it is not possible to draw any well-founded conclusions from these studies. Reasons for a possible additional benefit of adding a macrolide to the therapy could include: a higher prevalence of undiagnosed atypical pathogens, the anti-inflammatory effects of macrolides, and resistance of the main pathogens against beta-lactam antibiotics. None of these appear to play a significant role. There is no need to revise Dutch guidelines.
Insights
Current guidelines recommend beta-lactam antibiotics for Streptococcus pneumoniae pneumonia and macrolides for atypical pathogens. Evidence does not support adding macrolides to beta-lactam therapy for community-acquired pneumonia.
Area of Science:
- Infectious Diseases
- Pharmacology
- Internal Medicine
Context:
- Community-acquired pneumonia (CAP) is a significant cause of hospitalization and mortality in adults.
- Current treatment guidelines recommend beta-lactam antibiotics for Streptococcus pneumoniae and macrolides for atypical pathogens.
- Combination therapy with beta-lactams and macrolides or fluoroquinolones is common practice in the US and other regions.
Purpose:
- To evaluate the scientific literature regarding the efficacy of adding macrolides to beta-lactam antibiotic therapy for community-acquired pneumonia.
- To determine if current Dutch guidelines for CAP treatment require revision based on available evidence.
Summary:
- The existing literature on CAP treatment primarily comprises retrospective studies.
- These studies suffer from potential selection bias and inconsistent outcomes, precluding well-founded conclusions.
- The potential benefits of adding macrolides, such as covering undiagnosed atypical pathogens, anti-inflammatory effects, or overcoming beta-lactam resistance, were not found to be significant.
Impact:
- The findings suggest that current Dutch guidelines for community-acquired pneumonia do not require revision.
- This research highlights the limitations of retrospective data in establishing definitive treatment protocols for CAP.
- Further well-designed studies may be needed to clarify the role of combination antibiotic therapy in CAP.